CRF announces late-breaking trials and first report investigations for TCT 2014

August 01, 2014

NEW YORK, NY - August 1, 2014 - The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place September 13 - 17, 2014 at the Walter E. Washington Convention Center in Washington, DC.

Clinical research data presented at TCT often direct the course of patient therapies. The studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Saturday, September 13; Sunday, September 14; Monday, September 15; and Tuesday, September 16.

Media are invited to attend TCT; press credentials and registration information can be found here: http://www.crf.org/tct/press/press-registration-form.

Saturday, September 13

Plenary Session V: Late-Breaking Clinical Trials I

11:00 AM-12:00 PM

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis
Samir R. Kapadia

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis
Matthew R. Reynolds

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Axel Linke

Plenary Session VI: First Reports I
12:00 PM-12:30 PM

The CoreValve US Pivotal Trial: Two-Year Results with a Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis
Steven J. Yakubov

ISAR-CLOSURE: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access
Stefanie Schulz

Sunday, September 14

Plenary Session XII: Late-Breaking Clinical Trials II

11:00 AM-12:00 PM

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease
Patrick W. Serruys

DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions
Shao Liang Chen

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents
Fernando Alfonso

Plenary Session XII: First Reports II
12:00 PM-12:30 PM

IVUS-CTO: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions
Yang-Soo Jang

OCT STEMI: A Prospective, Randomized Trial of Optical Coherence Tomography Guidance During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
Pavel Cervinka

Monday, September 15

Plenary Session XIX: Late-Breaking Clinical Trials III

11:10 AM-12:06 PM

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention
Yaling Han

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation
Nikolaus Sarafoff

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation
Antonio Colombo

Plenary Session XX: First Reports III
12:06 PM-12:36 PM

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Tracy Y. Wang

VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Gregg W. Stone

Tuesday, September 16

Plenary Session XXVI: Late-Breaking Clinical Trials IV

11:00 AM-12:00 PM

PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura
David Hildick-Smith

Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension
Steffen Desch

EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Eric J. Dippel

Plenary Session XXVII: First Reports IV
12:00 PM-12:30 PM

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease
Yaling Han

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease
Stéphane Cook
-end-
To view the complete TCT agenda, visit: http://www.crf.org/tct/agenda/tct-program.

Receive updates on Twitter: http://twitter.com/TCTConference

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.

Cardiovascular Research Foundation

Related Coronary Articles from Brightsurf:

Does coronary microvascular spasm exist?
In a new publication from Cardiovascular Innovations and Applications; Fabian Guenther, Andreas Seitz, Valeria Martínez Pereyra, Raffi Bekeredjian, Udo Sechtem and Peter Ong from the Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany consider whether coronary microvascular spasm exists.

Associations between vaspin levels and coronary artery disease
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0565, Lutfu Askin, Okan Tanriverdi, Hakan Tibilli and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider associations between vaspin levels and coronary artery disease.

Mayo Clinic study looks at changes in outcomes for coronary revascularization
The most common type of heart disease -- coronary artery disease -- affects 6.7% of adults and accounts for 20% of 2 in 10 deaths of adults under age 65.

Selective coronary angiography following cardiac arrest
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Coronary calcium levels a better predictor of patients at risk for coronary heart disease
A new study presented at the American Heart Association Scientific Session conference found that testing a patient's coronary calcium levels is a better predictor of blocked coronary arteries at risk for a heart attack and the need for revascularization than standard risk-assessment equations used in medical practice today.

Novel imaging biomarker to help predict coronary inflammation
Researchers at Cleveland Clinic, University of Oxford and University of Erlangen have identified a novel imaging biomarker, which has been found to be able to predict all-cause and cardiac mortality by measuring inflammation of fatty tissue surrounding the coronary arteries.

The danger of coronary artery compression in children is more common than we think
The incidence of coronary artery compression in children fitted with epicardial pacemakers may be slightly more common than previously believed, say noted cardiologists.

Study shows taking aspirin before or after coronary
New research presented at this year's Euroanaesthesia congress in Copenhagen, Denmark shows that in patients undergoing a coronary artery bypass graft (CABG) surgery, taking aspirin before and after surgery is associated with an 18 percent to 34 percent reduced mortality risk after four years.

Coronary heart disease: DMP could be extended by two topics
Almost all health care aspects need to be updated. The already third search update for guidelines shows that their number and quality have increased notably in 10 years.

Analysis of the 9p21.3 sequence associated with coronary artery disease
Before a conclusive link between the SDs and the cardiovascular diseases can be made, further analysis is required on the CAD interval in more patients with coronary artery disease and in the human population, using the TAR cloning technique in combination with qPCR or Droplet digital PCR developed in this work.

Read More: Coronary News and Coronary Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.